Rapid SARS-CoV-2 test from Cepheid receives EUA from FDA
by Press Release from Outbreak News Today on (#5131A)
Cepheid announced Saturday it has received Emergency Use Authorization (EUA) from the U.S. Food & Drug Administration (FDA) for Xpert(R) Xpress SARS-CoV-2, a rapid molecular diagnostic test for qualitative detection of SARS-CoV-2, the virus causing COVID-19. The test has been designed to operate on any of Cepheid's more than 23,000 automated GeneXpert(R) Systems worldwide, with a detection time of ["]
The post Rapid SARS-CoV-2 test from Cepheid receives EUA from FDA appeared first on Outbreak News Today.